Neurotech Advances Phase 3 ASD Trial, Cuts Loss 38%, Raises $3.75M

Phase 3 Trial Launch Marks Clinical Evolution

Neurotech International (ASX:NTI) has taken a significant step forward in its clinical development journey, launching the registration-enabling Phase 3 "Beyond Harmony" trial for its broad-spectrum oral cannabinoid therapy NTI164 targeting Autism Spectrum Disorder (ASD). The trial commenced at Monash Children's Hospital in March 2026 following regulatory approvals, enrolling children with moderate-to-severe ASD to assess core symptom improvements and neuroinflammatory markers. This move signals Neurotech’s transition from early clinical signals to late-stage evidence generation aimed at regulatory submissions in Australia and the US.

Financial Performance Reflects Strategic Progress

For the year ended 30 June 2026, Neurotech reported an 86% surge in revenues to $4.81 million, primarily fueled by a $4.73 million increase in R&D grant income. Meanwhile, the company trimmed its net loss by 38% to $6.54 million, reflecting disciplined expense management despite heavy investment in research and development, which accounted for over $9 million of expenditure. Cash reserves stood at $2.39 million at year-end, supported by placements totaling approximately $3.75 million during the year and a secured $3.15 million loan post-year-end against anticipated R&D tax incentives.

Regulatory Milestones and Intellectual Property Strengthening

July 2026 brought a major regulatory milestone as the US Food and Drug Administration cleared Neurotech’s Investigational New Drug (IND) application for NTI164, authorising clinical development in the US. This clearance paves the way for a complementary US population pharmacokinetic study designed to augment the Australian Phase 3 trial data package. Concurrently, the US Patent and Trademark Office issued Notices of Allowance for two patent applications covering NTI164’s methods for reducing neuroinflammation and treating ASD, expected to extend intellectual property protection through to 2042 once granted.

Broader Clinical and Commercial Development Efforts

Beyond ASD, Neurotech has advanced its pipeline in Rett Syndrome and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), with peer-reviewed publications supporting NTI164’s anti-inflammatory and neuroprotective mechanisms. The company’s Authorised Prescriber program in Australia continues to provide controlled access to NTI164, generating real-world clinical data while positioning the therapy within evolving regulatory frameworks. The company also announced the appointment of Mark Davies as Executive Chairman in August 2026, reflecting a strategic shift towards more active leadership in clinical, regulatory, and capital markets execution.

Funding Secured to Support Upcoming Milestones

Neurotech’s funding strategy has seen success with a $4.5 million placement announced in August 2026, backed by existing and new institutional investors, to primarily finance the Phase 3 ASD trial and associated regulatory activities. This capital injection, combined with existing cash and the R&D tax incentive loan, is expected to sustain operations through to topline data readout from the Phase 3 trial, a critical inflection point for the company’s development trajectory.